A novel process driving Alzheimer's disease validated in a mouse model: Therapeutic potential

The neuronal mechanism driving Alzheimer's disease (AD) is incompletely understood.

[1]  D. Praticò,et al.  Glycogen synthase kinase-3 signaling in Alzheimer's disease. , 2020, Biochimica et biophysica acta. Molecular cell research.

[2]  Kurt R. Lehner,et al.  Forebrain Cholinergic Signaling Regulates Innate Immune Responses and Inflammation , 2019, Front. Immunol..

[3]  B. Winters,et al.  Dissociable cognitive impairments in two strains of transgenic Alzheimer’s disease mice revealed by a battery of object-based tests , 2019, Scientific Reports.

[4]  T. O'Leary,et al.  Age‐related deterioration of motor function in male and female 5xFAD mice from 3 to 16 months of age , 2018, Genes, brain, and behavior.

[5]  R. Nowakowski,et al.  Sex‐biased hippocampal pathology in the 5XFAD mouse model of Alzheimer's disease: A multi‐omic analysis , 2018, The Journal of comparative neurology.

[6]  Jessica M. Hoffman,et al.  Is antagonistic pleiotropy ubiquitous in aging biology? , 2018, Evolution, medicine, and public health.

[7]  B. Lamb,et al.  Inflammation as a central mechanism in Alzheimer's disease , 2018, Alzheimer's & dementia.

[8]  S. Greenfield,et al.  A Multidisciplinary Approach Reveals an Age-Dependent Expression of a Novel Bioactive Peptide, Already Involved in Neurodegeneration, in the Postnatal Rat Forebrain , 2018, Brain sciences.

[9]  S. Greenfield,et al.  Modulatory Effects of a Novel Cyclized Peptide in Reducing the Expression of Markers Linked to Alzheimer's Disease , 2018, Front. Neurosci..

[10]  M. Mesulam,et al.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. , 2018, Brain : a journal of neurology.

[11]  B. Zlokovic,et al.  Alzheimer’s disease: A matter of blood–brain barrier dysfunction? , 2017, The Journal of experimental medicine.

[12]  Gabriela Constantin,et al.  The blood-brain barrier in Alzheimer's disease , 2017, Neurobiology of Disease.

[13]  S. Greenfield,et al.  (II) Physiological profiling of an endogenous peptide in the basal forebrain: Age-related bioactivity and blockade with a novel modulator , 2016, Neuropharmacology.

[14]  S. Greenfield,et al.  (I) Pharmacological profiling of a novel modulator of the α7 nicotinic receptor: Blockade of a toxic acetylcholinesterase-derived peptide increased in Alzheimer brains , 2016, Neuropharmacology.

[15]  R. Vassar,et al.  Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level , 2015, Molecular Neurodegeneration.

[16]  F. Schmitt,et al.  Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models , 2014, Front. Genet..

[17]  A. Maelicke,et al.  Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer’s Disease , 2014, PloS one.

[18]  Susan Greenfield,et al.  High-resolution spatio-temporal bioactivity of a novel peptide revealed by optical imaging in rat orbitofrontal cortex in vitro: Possible implications for neurodegenerative diseases , 2013, Neuropharmacology.

[19]  Oliver Wirths,et al.  Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease , 2012, Neurobiology of Aging.

[20]  M. Antunes,et al.  The novel object recognition memory: neurobiology, test procedure, and its modifications , 2011, Cognitive Processing.

[21]  D. Small,et al.  Revisiting the Role of Acetylcholinesterase in Alzheimer’s Disease: Cross-Talk with P-tau and β-Amyloid , 2011, Front. Mol. Neurosci..

[22]  M. Bielefeld-Sévigny.  AlphaLISA immunoassay platform- the "no-wash" high-throughput alternative to ELISA. , 2009, Assay and drug development technologies.

[23]  S. Greenfield,et al.  Upregulation of α7 Nicotinic Receptors by Acetylcholinesterase C-Terminal Peptides , 2009, PloS one.

[24]  D. Vaux,et al.  Heterologous Amyloid Seeding: Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease , 2007, PloS one.

[25]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[26]  L. Galluzzi,et al.  Mechanisms of cytochrome c release from mitochondria , 2006, Cell Death and Differentiation.

[27]  J. Aleu,et al.  Effect of galantamine on the human α7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity , 2005, British journal of pharmacology.

[28]  K. Jellinger.  Head injury and dementia , 2004, Current opinion in neurology.

[29]  E. Mann,et al.  A novel peptide modulates α7 nicotinic receptor responses: implications for a possible trophic‐toxic mechanism within the brain , 2004, Journal of neurochemistry.

[30]  S. Greenfield,et al.  Bioactivity of a peptide derived from acetylcholinesterase in hippocampal organotypic cultures , 2004, Experimental Brain Research.

[31]  S. Greenfield,et al.  A peptide derived from acetylcholinesterase induces neuronal cell death: characterisation of possible mechanisms , 2003, Experimental Brain Research.

[32]  D. Vaux,et al.  Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide. , 2002, Biochemistry.

[33]  S. Greenfield,et al.  Parkinson’s disease, Alzheimer’s disease and motor neurone disease: identifying a common mechanism , 2002, Neuroscience.

[34]  C. Culmsee,et al.  Neuronal apoptosis in Alzheimer ’ s disease , 2001 .

[35]  J. Born,et al.  Brain potential changes after intranasal vs. intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans , 1996, Biological Psychiatry.

[36]  George Perry,et al.  Free radical damage, iron, and Alzheimer's disease , 1995, Journal of the Neurological Sciences.

[37]  H. Soreq,et al.  Transgenic expression of human acetylcholinesterase induces progressive cognitive deterioration in mice , 1995, Current Biology.

[38]  M. Schramm,et al.  The Quantity of Calcium that Appears to Induce Neuronal Death , 1994, Journal of neurochemistry.

[39]  T. Arendt,et al.  Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development—A study of molecular forms , 1992, Neurochemistry International.

[40]  S. Greenfield,et al.  Ultrastructural localization of acetylcholinesterase in substantia nigra: A comparison between rat and guinea pig , 1984, The Journal of comparative neurology.

[41]  George C. Williams,et al.  PLEIOTROPY, NATURAL SELECTION, AND THE EVOLUTION OF SENESCENCE , 1957, Science of Aging Knowledge Environment.

[42]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.